Node-Negative
The Report:
A detailed Breast Recurrence Score® report containing personalized, treatment-selection insights is generated for each patient.
The Score:
The Recurrence Score® result is based on a continuous scale of 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit for that patient.
The Endpoints:
- Assesses the 9-year risk of distant recurrence in node-negative patients1
- Risk of 5-year distant recurrence or 5-year risk of distant recurrence or mortality for node-positive patients2
- Likelihood that chemotherapy will benefit your patient3,4
How your patient’s Recurrence Score result is generated
The Breast Recurrence Score test is a genomic test that measures the expression of cancer-related genes in your patient’s tumor. Your patient’s Recurrence Score result is based on the expression of 21 specific genes from tumor tissue removed during the surgery or core biopsy. Looking at the expression of this unique set of genes, the Recurrence Score result provides important information about how likely your patient’s cancer is to return and about your patient’s likelihood to benefit from chemotherapy
| BREAKDOWN OF THE 21 GENES INCLUDED IN THE ASSAY | ||||
| 16 Breast Cancer-Related Genes | ||||
| Estrogen | Proliferation | HER2 | Invasion | Others |
| ER | Ki-67 | GRB7 | Stromelysin 3 | CD68 |
| PR | STK15 | HER2 | Cathepsin L2 | GSTM1 |
| Bc12 | Survivin | BAG1 | ||
| SCUBE12 | Cyclin B1 | |||
| MYBL2 | ||||
| 5 Reference Genes | ||||
| Beta-actin | GAPDH | RPLPO | GUS | TFRC |
The relevance of the estrogen receptor (ER) score by reverse transcription polymerase chain reaction (RT-PCR)
A strong predictor of tamoxifen benefit in node-negative patients
While the Recurrence Score result and corresponding average rate of distant recurrence accounts for this effect of tamoxifen (in addition to the tumor’s fundamental prognosis), the single-gene ER score may also help clarify the magnitude of tamoxifen benefit.5
Explore the patient report
The Oncotype DX Breast Recurrence Score® patient report provides 3 points of clarity to aid in chemotherapy treatment decisions for node-negative and node-positive breast cancer patients.
-
-
Node-Positive
 |
Recurrence Score resultThe Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumor sample. |
 |
PrognosisPatient’s individualized risk of distant recurrence when treated with endocrine therapy alone.* |
 |
PredictionThe Group Average Absolute Chemotherapy Benefit is the potential reduction in risk of distant recurrence across all ages within this range of Recurrence Score results when chemotherapy is added.* |
This is a sample report of a node-negative patient.
*Based on the TAILORx trial or the NSABP B-20 study.
|
Recurrence Score resultThe Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumor sample. |
|
PrognosisPatient’s individualized risk of distant recurrence or individualized risk of recurrence or mortality when treated with endocrine therapy alone.* |
|
PredictionThe Group Average Absolute Chemotherapy Benefit is the potential reduction in risk of distant recurrence across all ages within this range of Recurrence Score results when chemotherapy is added.* |
Getting the results
Most Breast Recurrence Score reports are available within 2 weeks from the date the specimen is received in the Exact Sciences lab. You can access the results through the Provider Hub or receive the report by fax.
The Oncotype DX Breast Recurrence Score test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration.
-
References
